ReviewExpert review of clinical immunology2010
Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease.
Review in Expert review of clinical immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 55 citations in OpenAlex.
- Article
- Inflammation: Is It a Healer, Confounder, or a Promoter of Cardiometabolic Risks?Biomolecules · 2024Review
- Article
- Inflammasome-targeting natural compounds in inflammatory bowel disease: Mechanisms and therapeutic potential.Frontiers in immunology · 2022Review
- An Algorithmic Approach to Perineal Reconstruction.Plastic and reconstructive surgery. Global open · 2019Article
- Contribution of Wound-Associated Cells and Mediators in Orchestrating Gastrointestinal Mucosal Wound Repair.Annual review of physiology · 2019Review
- Impaired resolution of DSS-induced colitis in mice lacking the glucocorticoid receptor in myeloid cells.PloS one · 2018Article
- CD64: An Attractive Immunotherapeutic Target for M1-type Macrophage Mediated Chronic Inflammatory Diseases.Biomedicines · 2017Review
- Review on modeling anti-antibody responses to monoclonal antibodies.Journal of pharmacokinetics and pharmacodynamics · 2014Review
- Simplification of complex physiologically based pharmacokinetic models of monoclonal antibodies.The AAPS journal · 2014Article
- Therapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis.Clinical and experimental gastroenterology · 2014Article
- IgG4 production against adalimumab during long term treatment of RA patients.Journal of clinical immunology · 2012Article
- Biopharmaceuticals and monoclonal antibodies in oncology trials--a cross-sectional analysis.Protein engineering, design & selection : PEDS · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Crohn's disease and ulcerative colitis are complex diseases that have required the use of multiple modalities to aid in treatment. With an increasing understanding of the underlying pathogenetic mechanisms and identification of specific therapeutic targets, monoclonal antibody treatment has been an ideal strategy for inducing and maintaining remission in these patients. This article addresses approved agents and the supporting data justifying their use in Crohn's disease and ulcerative colitis, the safety of and immunologic reactions to these agents, as well as newer agents for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.